| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| CRO服务(元) | 7,620,771.42 | 15,824,568.96 | - | 8,748,759.91 | 1,984,056.56 |
| 靶点及因子类蛋白(元) | 29,129,077.19 | 59,606,075.08 | 27,215,914.45 | 57,037,728.73 | 27,983,146.15 |
| 酶及试剂(元) | 19,769,434.84 | 70,001,075.46 | 38,269,251.20 | 132,126,202.72 | 74,978,341.59 |
| 重组抗体(元) | 3,086,286.36 | 7,618,123.50 | 3,823,272.84 | 66,416,028.39 | 61,356,099.41 |
| 技术服务(元) | - | - | 5,338,621.13 | - | - |
| 营业成本(元) | |||||
| CRO服务(元) | 5,101,127.77 | 13,014,221.16 | - | - | 3,626,770.92 |
| 靶点及因子类蛋白(元) | 8,608,361.97 | 13,065,517.78 | - | - | 5,061,568.73 |
| 酶及试剂(元) | 7,640,946.91 | 9,980,635.67 | - | - | 7,326,885.38 |
| 重组抗体(元) | 480,817.96 | 1,141,415.23 | - | - | 1,592,034.63 |
| 技术服务(元) | - | - | - | - | - |
| 毛利(元) | |||||
| CRO服务(元) | 2,519,643.65 | 2,810,347.80 | - | - | -1,642,714.36 |
| 靶点及因子类蛋白(元) | 20,520,715.22 | 46,540,557.30 | - | - | 22,921,577.42 |
| 酶及试剂(元) | 12,128,487.93 | 60,020,439.79 | - | - | 67,651,456.21 |
| 重组抗体(元) | 2,605,468.40 | 6,476,708.27 | - | - | 59,764,064.78 |
| 技术服务(元) | - | - | - | - | - |
| 毛利率(%) | |||||
| CRO服务(%) | 33.06 | 17.76 | - | - | -82.80 |
| 靶点及因子类蛋白(%) | 70.45 | 78.08 | - | - | 81.91 |
| 酶及试剂(%) | 61.35 | 85.74 | - | - | 90.23 |
| 重组抗体(%) | 84.42 | 85.02 | - | - | 97.41 |
| 技术服务(%) | - | - | - | - | - |
| 收入构成(%) | |||||
| CRO服务(%) | 12.79 | 10.34 | - | 3.31 | 1.19 |
| 靶点及因子类蛋白(%) | 48.87 | 38.95 | 36.46 | 21.58 | 16.83 |
| 酶及试剂(%) | 33.17 | 45.74 | 51.27 | 49.99 | 45.09 |
| 重组抗体(%) | 5.18 | 4.98 | 5.12 | 25.13 | 36.89 |
| 技术服务(%) | - | - | 7.15 | - | - |
| 毛利构成(%) | |||||
| CRO服务(%) | 6.67 | 2.43 | - | - | -1.10 |
| 靶点及因子类蛋白(%) | 54.32 | 40.17 | - | - | 15.42 |
| 酶及试剂(%) | 32.11 | 51.81 | - | - | 45.50 |
| 重组抗体(%) | 6.90 | 5.59 | - | - | 40.19 |
| 技术服务(%) | - | - | - | - | - |